MicroRNA-200c Nanoparticles Sensitized Gastric Cancer Cells to Radiotherapy by Regulating PD-L1 Expression and EMT

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013. doi:10.1001/jamaoncol.2018.001329543932
   PubMed Web of Science ®Google Scholar
• Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–2471. doi:10.1016/S0140-6736(17)31827-528993052
   PubMed Web of Science ®Google Scholar
• Saito H, Kono Y, Murakami Y, et al. Highly activated PD-1/PD-L1 pathway in gastric cancer with PD-L1 expression. Anticancer Res. 2018;38(1):107–112. doi:10.21873/anticanres.1219729277762
   PubMed Web of Science ®Google Scholar
• Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16(7):795–803. doi:10.1016/S1470-2045(15)00054-626095785
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74(19):5458–5468. doi:10.1158/0008-5472.CAN-14-125825274032
   PubMed Web of Science ®Google Scholar
• Sun LL, Yang RY, Li CW, et al. Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. Am J Cancer Res. 2018;8(7):1307–1316.30094103
   PubMed Web of Science ®Google Scholar
• Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903. doi:10.1016/S1470-2045(17)30380-728551359
   PubMed Web of Science ®Google Scholar
• Theys J, Jutten B, Habets R, et al. E-cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol. 2011;99(3):392–397. doi:10.1016/j.radonc.2011.05.04421680037
   PubMed Web of Science ®Google Scholar
• Hao Y, Baker D, Ten Dijke P. TGF-beta-mediated epithelial-mesenchymal transition and cancer metastasis. Int J Mol Sci. 2019;20(11). doi:10.3390/ijms20112767
   Web of Science ®Google Scholar
• Ihling C, Naughton B, Zhang Y, et al. Observational study of PD-L1, TGF-beta, and immune cell infiltrates in hepatocellular carcinoma. Front Med. 2019;6:15. doi:10.3389/fmed.2019.00015
   Web of Science ®Google Scholar
• Liu Q, Li RT, Qian HQ, et al. Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. Biomaterials. 2013;34(29):7191–7203. doi:10.1016/j.biomaterials.2013.06.00423806972
   PubMed Web of Science ®Google Scholar
• Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5(1):5241. doi:10.1038/ncomms624125348003
   PubMedGoogle Scholar
• Muthiah M, Park IK, Cho CS. Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics. Expert Opin Drug Deliv. 2013;10(9):1259–1273. doi:10.1517/17425247.2013.79864023826971
   PubMed Web of Science ®Google Scholar
• Yang Y, Pan X, Lei W, et al. Regulation of transforming growth factor-beta 1-induced apoptosis and epithelial-to-mesenchymal transition by protein kinase A and signal transducers and activators of transcription 3. Cancer Res. 2006;66(17):8617–8624. doi:10.1158/0008-5472.CAN-06-130816951175
   PubMed Web of Science ®Google Scholar
• Leight JL, Wozniak MA, Chen S, Lynch ML, Chen CS. Matrix rigidity regulates a switch between TGF-beta1-induced apoptosis and epithelial-mesenchymal transition. Mol Biol Cell. 2012;23(5):781–791. doi:10.1091/mbc.E11-06-053722238361
   PubMed Web of Science ®Google Scholar
• Yang Y, Pan X, Lei W, Wang J, Song J. Transforming growth factor-beta1 induces epithelial-to-mesenchymal transition and apoptosis via a cell cycle-dependent mechanism. Oncogene. 2006;25(55):7235–7244. doi:10.1038/sj.onc.120971216799646
   PubMed Web of Science ®Google Scholar
• Park NR, Cha JH, Jang JW, et al. Synergistic effects of CD44 and TGF-beta1 through AKT/GSK-3beta/beta-catenin signaling during epithelial-mesenchymal transition in liver cancer cells. Biochem Biophys Res Commun. 2016;477(4):568–574. doi:10.1016/j.bbrc.2016.06.07727320862
   PubMed Web of Science ®Google Scholar
• Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382–386.30089911
   PubMed Web of Science ®Google Scholar
• Bristow RG, Alexander B, Baumann M, et al. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. Lancet Oncol. 2018;19(5):e240–e251. doi:10.1016/S1470-2045(18)30096-229726389
   PubMed Web of Science ®Google Scholar
• Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–377. doi:10.1038/nature1429225754329
   PubMed Web of Science ®Google Scholar
• Sharabi AB, Nirschl CJ, Kochel CM, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2015;3(4):345–355. doi:10.1158/2326-6066.CIR-14-019625527358
   PubMed Web of Science ®Google Scholar
• Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005;6(5):376–385. doi:10.1038/nrm164415852042
   PubMed Web of Science ®Google Scholar
• Martinez-Ciarpaglini C, Oltra S, Rosello S, et al. Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression. Mod Pathol. 2019;32(2):306–313. doi:10.1038/s41379-018-0124-530206410
   PubMed Web of Science ®Google Scholar
• Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006;98(24):1777–1785. doi:10.1093/jnci/djj49517179479
   PubMedGoogle Scholar
• Meadows KN, Iyer S, Stevens MV, et al. Akt promotes endocardial-mesenchyme transition. J Angiogenes Res. 2009;1(1):2. doi:10.1186/2040-2384-1-219946410
   PubMedGoogle Scholar
• Kang YK, Bang YJ, Kondo S, et al. Safety and tolerability of bintrafusp alfa, a bifunctional fusion protein targeting TGFbeta and PD-L1, in Asian patients with pretreated recurrent or refractory gastric cancer. Clin Cancer Res. 2020;26(13):3202–3210. doi:10.1158/1078-0432.CCR-19-380632299818
   PubMed Web of Science ®Google Scholar
• Grenda A, Krawczyk P. New dancing couple: PD-L1 and MicroRNA. Scand J Immunol. 2017;86(3):130–134. doi:10.1111/sji.1257728675453
   PubMed Web of Science ®Google Scholar
• Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008;22(7):894–907. doi:10.1101/gad.164060818381893
   PubMed Web of Science ®Google Scholar
• Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol. 2012;39(4):461–472. doi:10.1053/j.seminoncol.2012.05.01122846863
   PubMed Web of Science ®Google Scholar
• Li L, Liu C, Amato RJ, Chang JT, Du G, Li W. CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression. Oncotarget. 2014;5(21):10840–10853. doi:10.18632/oncotarget.253525333262
   PubMedGoogle Scholar
• Dang H, Ding W, Emerson D, Rountree CB. Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics. BMC Cancer. 2011;11(1):396. doi:10.1186/1471-2407-11-39621929801
   PubMedGoogle Scholar
• Brown RL, Reinke LM, Damerow MS, et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 2011;121(3):1064–1074. doi:10.1172/JCI4454021393860
   PubMed Web of Science ®Google Scholar
• Xu H, Tian Y, Yuan X, et al. The role of CD44 in epithelial-mesenchymal transition and cancer development. Onco Targets Ther. 2015;8:3783–3792. doi:10.2147/OTT.S9547026719706
   PubMed Web of Science ®Google Scholar
• Cheng C, Sharp PA. Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol Cell Biol. 2006;26(1):362–370. doi:10.1128/MCB.26.1.362-370.200616354706
   PubMed Web of Science ®Google Scholar
• Tang H, Liang Y, Anders RA, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest. 2018;128(2):580–588. doi:10.1172/JCI9606129337303
   PubMed Web of Science ®Google Scholar